Leveraging its Direct-to-Consumer Success, DarioHealth to Offer Organizations an Open Platform that Digitizes a Better Clinical Approach for Targeted Healthcare

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it is increasing its B2B2C offering by facilitating organizations to digitize targeted healthcare solutions in patients with diabetes. The strategic move comes on the eve of Diabetes Awareness Month, and DarioHealth has officially launched its new corporate website http://www.dariohealth.com to showcase its first-class capabilities.

The new platform, called Dario Engage, helps healthcare providers in all aspects of user engagement, including enrollment, coaching and ongoing communications with the end-users. With tens of thousands of active users worldwide via its direct-to-consumer efforts, DarioHealth has built up an impressive knowledgebase to leverage as it expands its reach.

Erez Raphael, Chairman and CEO of DarioHealth, commented, "We are really excited to build upon our direct-to-consumer success and provide a wholly unique solution that is currently desired and unmet by healthcare providers. This is a natural evolution of our business, because Dario Engage expands our capabilities in the mobile health market as we continue to utilize data management to improve the lives of those suffering from chronic health conditions.

"DarioHealth offers an exceptional proposition in that we can help coaching companies, providers and employers by offering them an open platform, thereby empowering them to implement their own clinical expertise in a more digital, user-centric and efficient way. We believe this approach will address two burgeoning issues: improving quality of health for individuals, which in turn will lower healthcare costs across the spectrum."

The Dario Engage platform is positioned for improved services that is more time- and cost-effective for its users. DarioHealth removes the guesswork with user-centric, data-driven health solutions allowing each person to get the right care, at the right time, to effectively manage their chronic conditions.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the benefits of Dario Engage, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.